Literature DB >> 28655791

Nrf2 Mutagenic Activation Drives Hepatocarcinogenesis.

Hoang Kieu Chi Ngo1, Do-Hee Kim1, Young-Nam Cha2, Hye-Kyung Na3, Young-Joon Surh4,5,6.   

Abstract

Nrf2, a master regulator of oxidative stress, is considered a prominent target for prevention of hepatocellular carcinoma (HCC), one of the leading causes of cancer-related deaths worldwide. Here we report that Nrf2-deficient mice resisted diethylnitrosamine (DEN)-induced hepatocarcinogenesis without affecting P450-mediated metabolic activation of DEN. Nrf2 expression, nuclear translocation, and transcriptional activity were enhanced in liver tumors. Overactivated Nrf2 was required for hepatoma growth in DEN-induced HCC. Following DEN treatment, Nrf2 genetic disruption reduced expression of pentose phosphate pathway-related enzymes, the depletion of which has been associated with an amelioration of HCC incidence. Conversely, enhanced Nrf2 activity was attributable to alterations in the ability to bind its endogenous inhibitor Keap1. Our findings provide a mechanistic rationale for Nrf2 blockade to prevent and possibly treat liver cancer. Cancer Res; 77(18); 4797-808. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28655791     DOI: 10.1158/0008-5472.CAN-16-3538

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

Review 1.  Oxidative Stress in Cancer.

Authors:  John D Hayes; Albena T Dinkova-Kostova; Kenneth D Tew
Journal:  Cancer Cell       Date:  2020-07-09       Impact factor: 31.743

Review 2.  Nrf2 in liver toxicology.

Authors:  Keiko Taguchi; Thomas W Kensler
Journal:  Arch Pharm Res       Date:  2019-11-28       Impact factor: 4.946

3.  Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice.

Authors:  Di Zhang; Jonathan Rennhack; Eran R Andrechek; Cheryl E Rockwell; Karen T Liby
Journal:  Antioxid Redox Signal       Date:  2018-04-16       Impact factor: 8.401

4.  Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma.

Authors:  Derek Lee; Iris Ming-Jing Xu; David Kung-Chun Chiu; Josef Leibold; Aki Pui-Wah Tse; Macus Hao-Ran Bao; Vincent Wai-Hin Yuen; Cerise Yuen-Ki Chan; Robin Kit-Ho Lai; Don Wai-Ching Chin; Daniel For-Fan Chan; Tan-To Cheung; Siu-Ho Chok; Chun-Ming Wong; Scott W Lowe; Irene Oi-Lin Ng; Carmen Chak-Lui Wong
Journal:  Hepatology       Date:  2019-03-21       Impact factor: 17.425

5.  The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase.

Authors:  Viraj R Sanghvi; Josef Leibold; Marco Mina; Prathibha Mohan; Marjan Berishaj; Zhuoning Li; Matthew M Miele; Nathalie Lailler; Chunying Zhao; Elisa de Stanchina; Agnes Viale; Leila Akkari; Scott W Lowe; Giovanni Ciriello; Ronald C Hendrickson; Hans-Guido Wendel
Journal:  Cell       Date:  2019-08-08       Impact factor: 66.850

Review 6.  Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics.

Authors:  Haichuan Wang; Xin Chen; Diego F Calvisi
Journal:  Expert Opin Ther Targets       Date:  2021-09-11       Impact factor: 6.797

7.  TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy.

Authors:  Michael R McLoughlin; David J Orlicky; Justin R Prigge; Pushya Krishna; Emily A Talago; Ian R Cavigli; Sofi Eriksson; Colin G Miller; Jean A Kundert; Volkan I Sayin; Rachel A Sabol; Joshua Heinemann; Luke O Brandenberger; Sonya V Iverson; Brian Bothner; Thales Papagiannakopoulos; Colin T Shearn; Elias S J Arnér; Edward E Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-16       Impact factor: 12.779

8.  Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.

Authors:  Junyan Tao; Yekaterina Krutsenko; Akshata Moghe; Sucha Singh; Minakshi Poddar; Aaron Bell; Michael Oertel; Aatur D Singhi; David Geller; Xin Chen; Amaia Lujambio; Silvia Liu; Satdarshan P Monga
Journal:  Hepatology       Date:  2021-06-21       Impact factor: 17.298

9.  NRF2: KEAPing Tumors Protected.

Authors:  Ray Pillai; Makiko Hayashi; Anastasia-Maria Zavitsanou; Thales Papagiannakopoulos
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

10.  Disruption of FBXL5-mediated cellular iron homeostasis promotes liver carcinogenesis.

Authors:  Yoshiharu Muto; Toshiro Moroishi; Kazuya Ichihara; Masaaki Nishiyama; Hideyuki Shimizu; Hidetoshi Eguchi; Kyoji Moriya; Kazuhiko Koike; Koshi Mimori; Masaki Mori; Yuta Katayama; Keiichi I Nakayama
Journal:  J Exp Med       Date:  2019-03-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.